News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
265,240 Results
Type
Article (13761)
Company Profile (101)
Press Release (251378)
Section
Business (88048)
Career Advice (465)
Deals (15343)
Drug Delivery (67)
Drug Development (36601)
Employer Resources (49)
FDA (6289)
Job Trends (6196)
News (150215)
Policy (14029)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (4)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (440)
Accelerated approval (2)
Adcomms (6)
Allergies (32)
Alliances (23216)
ALS (36)
Alzheimer's disease (389)
Antibody-drug conjugate (ADC) (37)
Approvals (6326)
Artificial intelligence (104)
Autoimmune disease (8)
Automation (3)
Bankruptcy (149)
Best Places to Work (4370)
BIOSECURE Act (9)
Biosimilars (55)
Biotechnology (40)
Bladder cancer (19)
Brain cancer (15)
Breast cancer (74)
Cancer (585)
Cardiovascular disease (70)
Career advice (407)
Career pathing (11)
CAR-T (21)
Cell therapy (85)
Cervical cancer (4)
Clinical research (30879)
Collaboration (325)
Compensation (138)
Complete response letters (17)
COVID-19 (757)
CRISPR (19)
C-suite (117)
Cystic fibrosis (35)
Data (604)
Denatured (15)
Depression (9)
Diabetes (77)
Diagnostics (1316)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (55)
Drug pricing (63)
Drug shortages (12)
Duchenne muscular dystrophy (33)
Earnings (32076)
Editorial (11)
Employer branding (4)
Employer resources (43)
Events (37405)
Executive appointments (359)
FDA (6686)
Featured Employer (20)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (205)
Gene editing (37)
Generative AI (8)
Gene therapy (99)
GLP-1 (339)
Government (1288)
Grass and pollen (2)
Guidances (15)
Healthcare (3565)
Huntington's disease (4)
IgA nephropathy (11)
Immunology and inflammation (34)
Indications (12)
Infectious disease (790)
Inflammatory bowel disease (54)
Inflation Reduction Act (6)
Influenza (13)
Intellectual property (45)
Interviews (59)
IPO (5874)
IRA (29)
Job creations (2050)
Job search strategy (373)
Kidney cancer (6)
Labor market (10)
Layoffs (177)
Leadership (3)
Legal (3429)
Liver cancer (19)
Lung cancer (79)
Lymphoma (52)
Machine learning (1)
Management (16)
Manufacturing (143)
MASH (31)
Medical device (1275)
Medtech (1277)
Mergers & acquisitions (9658)
Metabolic disorders (246)
Multiple sclerosis (20)
NASH (14)
Neurodegenerative disease (22)
Neuropsychiatric disorders (6)
Neuroscience (561)
NextGen: Class of 2025 (1586)
Non-profit (593)
Northern California (679)
Now hiring (7)
Obesity (140)
Opinion (118)
Ovarian cancer (21)
Pain (50)
Pancreatic cancer (13)
Parkinson's disease (44)
Partnered (7)
Patents (104)
Patient recruitment (28)
Peanut (10)
People (28884)
Pharmaceutical (64)
Pharmacy benefit managers (11)
Phase I (8037)
Phase II (13063)
Phase III (11726)
Pipeline (414)
Podcasts (46)
Policy (59)
Postmarket research (1401)
Preclinical (3210)
Press Release (25)
Prostate cancer (44)
Psychedelics (8)
Radiopharmaceuticals (120)
Rare diseases (158)
Real estate (2634)
Recruiting (17)
Regulatory (10089)
Reports (14)
Research institute (564)
Resumes & cover letters (55)
Rett syndrome (1)
RNA editing (2)
RSV (7)
Schizophrenia (35)
Series A (36)
Series B (11)
Service/supplier (3)
Sickle cell disease (31)
Southern California (695)
Special edition (6)
Spinal muscular atrophy (77)
Sponsored (6)
Startups (1627)
State (2)
Stomach cancer (3)
Supply chain (28)
Tariffs (10)
The Weekly (29)
United States (6892)
Vaccines (150)
Venture capitalists (13)
Webinars (10)
Weight loss (95)
Women's health (8)
Worklife (3)
Date
Today (46)
Last 7 days (275)
Last 30 days (966)
Last 365 days (12026)
2025 (3081)
2024 (12501)
2023 (14247)
2022 (19560)
2021 (20068)
2020 (19033)
2019 (14887)
2018 (11713)
2017 (13889)
2016 (13129)
2015 (15472)
2014 (12419)
2013 (10592)
2012 (11396)
2011 (11924)
2010 (10891)
Location
Africa (313)
Alabama (13)
Alaska (1)
Arizona (54)
Arkansas (3)
Asia (20091)
Australia (2605)
California (1641)
Canada (874)
China (230)
Colorado (65)
Connecticut (65)
Delaware (53)
Europe (39366)
Florida (307)
Georgia (36)
Idaho (9)
Illinois (186)
India (15)
Indiana (128)
Iowa (1)
Japan (86)
Kansas (55)
Kentucky (12)
Louisiana (1)
Maine (2)
Maryland (245)
Massachusetts (1423)
Michigan (28)
Minnesota (89)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (7)
New Hampshire (6)
New Jersey (725)
New Mexico (7)
New York (482)
North Carolina (380)
North Dakota (2)
Northern California (679)
Ohio (48)
Oklahoma (4)
Oregon (16)
Pennsylvania (415)
Puerto Rico (8)
Rhode Island (7)
South America (501)
South Carolina (2)
Southern California (695)
Tennessee (34)
Texas (219)
Utah (33)
Virginia (70)
Washington D.C. (29)
Washington State (112)
Wisconsin (14)
265,240 Results for "melior pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Melior Is Recognized as CRO of the Year by Life Sciences Review
Melior Discovery, Inc. announced that it has been selected as the CRO of the Year by Life Sciences Review magazine.
March 19, 2024
·
2 min read
Business
Melior Announces Substantial Additions to Its Management and Scientific Team
Melior Discovery, Inc. (Melior) announced today significant additions to its management organization.
April 12, 2022
·
3 min read
Business
Melior Pharmaceuticals Announces Execution of License Agreement for Armesocarb by Adhera Therapeutics
Melior Pharmaceuticals (Melior) announced that it completed a definitive licensing agreement with Adhera Therapeutics, Inc . (OTCPK: ATRX; Adhera) for Melior’s Parkinson’s disease (PD) candidate, MLR-1019 (armesocarb).
July 29, 2021
·
2 min read
Deals
Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 Diabetes
Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) is pleased to announce that it has entered into an agreement for the assignment of Adhera Therapeutics, Inc.’s (“Adhera’s”) rights to tolimidone (formerly coded MLR-1023) under an exclusive, worldwide, sub-licensable license from Melior Pharmaceuticals I, Inc. (“Melior”) to develop, manufacture, commercialize or otherwise exploit tolimidone.
November 27, 2023
·
8 min read
Deals
Melior Pharmaceuticals Announces Entry Into “Letter-of-Intent” for the Acquisition of Armesocarb by Adhera Therapeutics
Melior Pharmaceuticals (Melior) announced that it has signed a “letter of intent” with Adhera Therapeutics, Inc . (OTCPK: ATRX; Adhera) for the acquisition of Melior’s Parkinson’s disease (PD) candidate, MLR-1019 (armesocarb).
June 7, 2021
·
2 min read
Biodexa Announces Allowance of U.S. Patent Covering Tolimidone
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”)(Nasdaq: BDRX) today announced that the U.S. Patent and Trademark Office allowed U.S. patent application No. 16/546,595 titled “Prevention of Pancreatic Cell Degeneration” which was exclusively licensed to Biodexa by Melior Pharmaceuticals, Inc., along with other patents, in a transaction which closed in December 2023.
February 7, 2024
·
5 min read
Pharm Country
Melior Pharmaceuticals Receives IND Clearance from US FDA for COVID-19 Therapeutic
Melior’s therapeutic candidate, tolimidone, is: Expected to mitigate the probability and severity of COVID-19 subjects developing severe lung complications A repositioned drug that has been demonstrated to be safe and well-tolerated in previous clinical studies
March 9, 2021
·
2 min read
Drug Development
Trust, Tech, and Tomorrow: A Pharmaceutical Executive’s WEF Insights
Konstantina Katcheves, Senior VP of Innovative Global Business Development at Teva Pharmaceuticals brings insights from the World Economic Forum to SCOPE 2025.
March 5, 2025
·
1 min read
·
Lori Ellis
Mergers & acquisitions
Taiho Pharmaceutical Buys ADC Partner Araris for up to $1.1B Total
Japan-based Taiho Pharmaceutical has worked with Araris Biotech since 2023 developing antibody-drug conjugates for the oncology space.
March 17, 2025
·
2 min read
·
Dan Samorodnitsky
Drug Development
Melior Pharmaceuticals Awarded Grant for Advancing Pulmonary Therapeutic in COVID-19 Phase 2 Clinical Trial
Melior’s therapeutic candidate, tolimidone, is: Expected to mitigate the probability and severity of COVID-19 subjects developing severe lung complications A repositioned drug that has been demonstrated to be safe and well-tolerated in previous clinical studies
September 15, 2020
·
2 min read
1 of 26,524
Next